Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Opaganib · ABC294640

Small molecule · Inhibitor of sphingosine kinase-2 (SPHK2) · developed by RedHill Biopharma

Phase 2 Most advanced trial (none active)

3 Registered trials

What is Opaganib?

Opaganib is an orally available small-molecule inhibitor of sphingosine kinase-2 (SK2). It competitively binds to SK2, preventing phosphorylation of sphingosine to sphingosine 1-phosphate, thereby promoting apoptosis in cancer cells. It is studied in pancreatic cancer, hepatocellular carcinoma, and multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ABC294640, YelivaTM
Drug type: Small molecule
Targets: sphingosine kinase-2 (SPHK2)
Mechanism: Inhibitor of sphingosine kinase-2 (SPHK2)
Pathways: apoptosis, sphingosine 1-phosphate signaling
Therapy area: Oncology
Developer: RedHill Biopharma Limited
In trials of: APGE
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: DRG21OQ517

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02939807	Phase 2	Carcinoma, Hepatocellular	Withdrawn	APGE
NCT02757326	Phase 1/2	Multiple Myeloma	Terminated	APGE
NCT01488513	Phase 1	Pancreatic Cancer	Completed	APGE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, HepatocellularMultiple MyelomaPancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z